Rola inhibitorów acetylocholinesterazy w leczeniu zespołów otępiennych

Abstrakt

Progressive or persistent deficit of cognitive functions is the core clinical symptom of dementia. It is characterized by deterioration of memory mainly, but also other cognitive functions such as language skills, the presence of apraxia, agnosia and impaired spatial orientation. Advances in research in the last years contributed to creating new diagnostic and therapeutic guidelines in Alzheimer disease and other dementive syndromes. Despite the presence of extensive research on basic treatment in Alzheimer disease, from practical point of view 3 acetylocholinesterase inhibitors are important and NMDA-receptor antagonist-memantine. The use of these drugs is still controversial and raises many questions such as: when to start treatment, how effective the drugs are and how can we increase its effectiveness. We do not have univocal data confirming the use of drugs in mild cognitive impairment, and studies on the preventive action of ACE inhibitors are not very clear. In order to increase drug efficacy we need to consider new forms of drugs and combined treatment. The article presents the most important data on acetylocholinesterase inhibitors and their use in clinical practice.